September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.
Read More
Mobocertinib Global Maximum-Tolerated Dose is Found Tolerable in Japanese Patients With NSCLC
September 16th 2021Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.
Read More
FDA Approves Mobocertinib for EGFR Exon 20-Positive mNSCLC
September 15th 2021The FDA has granted approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.
Read More
Adjuvant Atezolizumab Improves DFS in Multiple Subgroups of Patients With Early-Stage NSCLC
September 10th 2021Data from an exploratory analysis of the phase 3 IMpower010 trial show the disease-free survival benefit of adjuvant atezolizumab in the treatment of early-stage non–small cell lung cancer.
Read More
Roundtable Roundup: Polling Physicians on Timing of Durvalumab in NSCLC
September 6th 2021During separate virtual live events, David R. Gandara, MD, and Alexander Spira, MD, PhD, discussed the timing of durvalumab in non–small cell lung cancer from the PACIFIC trial with participating physicians.
Read More
Roundtable Discussion: Antonoff Discusses Treatment Goals in NSCLC
September 4th 2021An otherwise healthy 60-year-old woman, who has quit smoking for 8 years after 13 pack years, presented with a nonproductive cough. The patient was diagnosed with non–small cell lung cancer. Oncologists discuss the scenario during a Case-Based Roundtable event.
Read More
How Prior Chemotherapy Impacts ICI Survival Outcomes in Patients With Lung Cancer
August 19th 2021Jorge Nieva, MD, discusses the results of the Impower010 study, which evaluated the efficacy of the checkpoint inhibitor atezolizumab after chemotherapy for lung cancer compared to best supportive care.
Watch